3 articles tagged with #drug-development. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Researchers have developed ClinicalReTrial, a multi-agent AI system that can redesign clinical trial protocols to improve success rates. The system demonstrated an 83.3% improvement rate in trial protocols with a mean 5.7% increase in success probability at minimal cost of $0.12 per trial.
Boston Children's Hospital and MIT researchers are collaborating to develop RNA-based treatments for ALS (amyotrophic lateral sclerosis), combining their biological expertise to advance therapeutic approaches. This interdisciplinary partnership leverages complementary research capabilities to address a neurodegenerative disease with limited current treatment options.
Inhibrx Biosciences (INBX) stock surged 17% following positive Phase 2 clinical trial results showing that INBRX-106 combination therapy doubled response rates in head and neck cancer patients, demonstrating meaningful therapeutic efficacy.
